Floating-Harbor syndrome (FHS) is a rare condition characterized by short stature, delayed osseous maturation, expressive-language deficits, and a distinctive facial appearance. Occurrence is generally sporadic, although parent-to-child transmission has been reported on occasion. Employing whole-exome sequencing, we identified heterozygous truncating mutations in SRCAP in five unrelated individuals with sporadic FHS. Sanger sequencing identified mutations in SRCAP in eight more affected persons. Mutations were de novo in all six instances in which parental DNA was available. SRCAP is an SNF2-related chromatin-remodeling factor that serves as a coactivator for CREB-binding protein (CREBBP, better known as CBP, the major cause of Rubinstein-Taybi syndrome [RTS]). Five SRCAP mutations, two of which are recurrent, were identified; all are tightly clustered within a small (111 codon) region of the final exon. These mutations are predicted to abolish three C-terminal AT-hook DNA-binding motifs while leaving the CBP-binding and ATPase domains intact. Our findings show that SRCAP mutations are the major cause of FHS and offer an explanation for the clinical overlap between FHS and RTS.
learning disability is present in most individuals, and language (both receptive and expressive) is typically more severely affected. The name ''Floating Harbor'' is a portmanteau of Boston Floating Hospital and Harbor General Hospital (Torrance, CA), the two institutions from which the initial case reports originated.
1,2 Of the 50 or so cases of FHS in the literature, the majority are sporadic, although four reported instances of parent-tochild transmission suggest that this is an autosomal-dominant disorder in at least some instances. [4] [5] [6] [7] Some authors have highlighted the clinical overlap between FHS and Rubinstein-Taybi syndrome (RTS [MIM 180849]), which shares several key features (short stature, a long nose with low-hanging columella, a thin vermilion border of the upper lip, and anomalous thumbs). 3, 7 Despite the recognition of FHS as a distinct clinical entity more than 25 years ago, no causative mutations have been identified to date.
To identify the genetic basis of FHS, we assembled a cohort of 13 unrelated probands, three of whom were previously reported. 4 The clinical details of these individuals are presented in Table 1 and Figure 1 . To identify FHS-causing mutations, we performed exome capture and high-throughput sequencing of five unrelated affected persons (probands 1-5). Approval of the study design was obtained from the institutional research ethics board (Children's Hospital of Eastern Ontario), and free and informed consent was obtained from each study subject (or parent, if appropriate) prior to enrollment. We performed exome target enrichment by using the Agilent SureSelect 50 Mb All Exon Kit, and sequencing (Illumina HiSeq) generated 35-40 Gbp of 100 bp paired-end reads Short philtrum per sample. Reads were preprocessed (trimmed) and aligned to hg19 (see Web Resources for list of tools). We used an inhouse annotation pipeline to identify coding and splicesite variants that met a minimum quality threshold (i.e., R20% of reads supported the variant). Next, we filtered the variants to exclude common polymorphisms (>1% minor-allele frequency) represented in dbSNP131, in the 1000 Genomes pilot release, or in 270 exomes sequenced for individuals with unrelated disorders at our center. Presuming FHS to be an autosomal-dominant condition, we identified genes containing a single rare variant in each of several probands in a combinatorial fashion. Table 2 lists the numbers of potential candidate genes containing rare variants in any n probands as n is increased. Of five sequenced individuals with classic FHS, we noted that all contained heterozygous truncating variants clustered in the final (34 th ) exon of a single gene, SRCAP (encoding SNF2-related CREBBP activator protein). To confirm SRCAP as the gene mutated in FHS, we identified SRCAP exon 34 mutations with Sanger sequencing in a validation cohort of eight more unrelated probands (Table 1 and Figure 2 ; Figure S1 , available online). All of these mutations are truncating (nonsense or frameshift) alleles, tightly clustered between codons 2,407 and 2,517; none are represented in dbSNP131, 1000 Genomes, or the National Heart, Lung, 8 In reporter assays, SRCAP is a potent coactivator for CREB and CBP-mediated transcription. 8, 9 In transgenic Drosophila, exogenous SRCAP colocalizes with transcriptionally active chromatin and augments CBP's presence at these sites.
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Figure 1. Floating-Harbor Syndrome Due to SRCAP Mutations Clinical photos depicting 9 of 13 unrelated FHS probands with a confirmed SRCAP mutation are shown with the characteristically triangular face, long eyelashes, typical nose (long and narrow nasal bridge, broad base, full tip, and low-hanging columella), short philtrum, wide mouth, thin vermilion border of the upper lip, short chin, and low-set, posteriorly rotated ears. Clinical details concerning all study participants are presented in Table 1 . Affinity-purified SRCAP precipitates as a large complex that catalyzes ATP-dependent substitution of the variant histone H2A.Z into nucleosomes. 11 This activity has been confirmed by knockdown experiments with natural promoters, and it is correlated with in vivo target-gene expression. 12 Separately, SRCAP has also been shown to transduce signals belonging to the nuclear (steroid) hormone receptor and Notch pathways, indicating that it has diverse roles in gene expression. 10, 13 In keeping with its multiple coactivator roles, SRCAP contains several discrete functional domains. [8] [9] [10] These domains include an SNF2-like ATPase, an N-terminal HSA (Helicase-SANT-associated) domain, and three C-terminal AT-hook DNA-binding motifs; the CBP interaction domain of SRCAP is located centrally (Figure 2 ). Given the structure of SRCAP, the nonrandom clustering of truncating mutations seen in our study participants is strongly suggestive of a dominant-negative disease mechanism due to loss of one or more critical domain(s), for instance the three C-terminal AT-hook motifs. Several more arguments support this. First, in reporter assays, the major transactivation function of SRCAP is located in a 655 residue C-terminal fragment abolished by FHS-causing truncations. 9 Second, expression of a construct solely consisting of the CBP interaction domain of SRCAP strongly inhibits CREB-mediated transactivation in a dominant-negative fashion. 9 Third, Figure 1) , and nearly all individuals have short stature and expressive-language impairment. Despite the remarkable similarity among mutations seen in our study subjects, cognitive outcomes ranging from ''normal'' to ''significant intellectual disability'' were reported. It is unclear whether genetic modifier(s) and/or currently unidentified environmental factors are responsible. Many of our study subjects had additional systemic malformations, particularly genitourinary (eight individuals) and cardiac (three individuals) malformations. Again, genotype-phenotype correlations explaining these features are lacking. Given that FHS is a dominant condition exhibiting a high de novo mutation rate, one might expect a paternal age effect to be present, and indeed the mean paternal age of the affected individuals was advanced (36.9 years; range: 29-44 years).
Importantly, our findings suggest a basis for the longrecognized phenotypic overlap between FHS and RTS, the latter of which is caused by alterations in CBP or its homolog, p300. [14] [15] [16] Because alterations in both CBP and SRCAP are expected to produce widespread target-gene dysregulation, further studies are needed before we can determine which transcriptional targets are primarily responsible for each phenotype and whether any of these might be valid therapeutic targets. The availability of a molecular test for FHS will greatly improve the reliability of a formerly challenging clinical diagnosis. Historically, a diagnosis of FHS has relied upon the presence of typical facial features because many other key findings (e.g., short stature and language impairment) are nonspecific. The advent of molecular diagnosis for this condition will allow us to gain a better appreciation of the true prevalence and phenotypic spectrum of FHS.
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